This is pretty much my only question / concern now. If bot successfully proceeds to phase 3 then we have the exact outcome everyone was hoping for - a drug that has been shown to be safe and effective with p3 trials now underway. However, looking at the structure of the EOP2 meeting with fda, it doesn't seem that there's any reason p3 would not be approved. The drug is 1. safe and it is 2. effective. This is true for both AU and US results. As far as I can see, these are the 2 main requirements for p3 progression, outside of assessing the structure / format of the p3 trial (which I expect would have actually benefited from p2 learnings / issues in the US). I have topped up at 0.11 and while frustrated by the SP at the moment, still very confident in this company and it's LT prospects.
Bot Chart, page-2557
-
- There are more pages in this discussion • 12,442 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.232M | 3.263M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 413183 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |